| Literature DB >> 32998007 |
Gianpiero D'Amico1, Francesco Giannini2, Mauro Massussi1, Matteo Tebaldi3, Alessandro Cafaro4, Alfonso Ielasi5, Fabio Sgura6, Federico De Marco7, Giulio G Stefanini8, Marco Ciardetti9, Francesco Versaci10, Roberto A Latini11, Salvatore Saccà12, Sergio Ghiringhelli13, Andrea Picchi14, Marco Cerrito15, Achille Gaspardone16, Giuseppe Tarantini17.
Abstract
The coronary sinus (CS) Reducer is a novel device designed for the management of patients with severe angina symptoms refractory to optimal medical therapy and not amenable to further revascularization. Aim of this study was to investigate the efficacy and the safety of the CS Reducer device in a real-world, multicenter, and country-level cohort of patients presenting with refractory angina pectoris. The study included patients affected by refractory angina pectoris who underwent CS Reducer implantation in 16 centers. Clinical follow-up was carried as per each center's protocol. One hundred eighty-seven patients were included. Technical and procedural success were achieved in 98% and 95%, respectively. Minor peri-procedural complications were recorded in 8 patients. During a median follow-up of 18.4 months, 135 (82.8%) patients demonstrated at least 1 CCS class reduction after Reducer implantation, and 80 (49%) patients at least 2 CCS class reduction. Mean CCS class improved from 3.05 ± 0.53 at baseline to 1.63 ± 0.98 at follow-up (p < 0.001). Treatment benefit was also reflected in a significant improvement in quality of life scores and in a reduction of the mean number of anti-ischemic drugs prescribed for patient. In conclusion, in this multicenter, country-level study, the implantation of CS Reducer in patients with refractory angina pectoris resulted to be safe and effective in reducing of angina pectoris and improving quality of life.Entities:
Mesh:
Year: 2020 PMID: 32998007 DOI: 10.1016/j.amjcard.2020.09.045
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778